Erasca (ERAS)
NASDAQ:ERAS
Want to see ERAS full AI Analyst Report?
ERAS Stock Chart & Stats
$19.01
-$0.05(-2.00%)
At close: 4:00 PM EST
$19.01
-$0.05(-2.00%)
Day’s Range― - ―
52-Week Range$1.06 - $24.28
Previous CloseN/A
Volume148.24K
Average Volume (3M)6.76M
Market Cap
$2.83B
Enterprise Value$2.80B
Total Cash (Recent Filing)$276.07M
Total Debt (Recent Filing)$47.14M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
May 07, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding310,799,560
10 Day Avg. Volume8,687,046
30 Day Avg. Volume6,757,213
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)3.24
Price to Sales (P/S)0.00
P/FCF Ratio-11.03
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.77K
Enterprise Value/Ebitda-22.20
Forecast
1Y Price Target
$20.64Price Target Upside8.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.43
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet And FundingA sizable equity raise strengthened the balance sheet and provides capital to advance monotherapy expansion and combination cohorts, reducing near-term financing risk for development milestones.
Clinical ActivityEarly clinical data show multiple partial tumor responses across diverse RAS-mutant tumors at low doses with a manageable safety profile, supporting proof of concept and potential for broader efficacy.
Licensing And Data AccessExpanded licensing rights and access to clinical data from China increase the available dataset and strategic flexibility, enabling a more comprehensive assessment of durability and global development control.
Bears Say
Competitive BenchmarkLate-stage success by a competing RAS therapy raises the clinical performance bar and increases the challenge for ERAS to demonstrate clear differentiation in efficacy or safety.
Durability And Applicability UncertaintyObserved responses remain preliminary with unclear durability and uncertain applicability across different RAS-mutant tumor types, leaving clinical outcomes and market potential unsettled.
Readout Timing And Valuation RiskLack of granular timing for the ERAS-0015 clinical readout combined with a stock price that already reflects a high probability of success amplifies downside risk if results are delayed or fail to meet expectations.
Erasca News
ERAS FAQ
What was Erasca’s price range in the past 12 months?
Erasca lowest stock price was $1.06 and its highest was $24.28 in the past 12 months.
What is Erasca’s market cap?
Erasca’s market cap is $2.83B.
When is Erasca’s upcoming earnings report date?
Erasca’s upcoming earnings report date is May 07, 2026 which is in 7 days.
How were Erasca’s earnings last quarter?
Erasca released its earnings results on Mar 12, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.107 by $0.007.
Is Erasca overvalued?
According to Wall Street analysts Erasca’s price is currently Undervalued.
Does Erasca pay dividends?
Erasca does not currently pay dividends.
What is Erasca’s EPS estimate?
Erasca’s EPS estimate is -0.1.
How many shares outstanding does Erasca have?
Erasca has 310,799,560 shares outstanding.
What happened to Erasca’s price movement after its last earnings report?
Erasca reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.107. Following the earnings report the stock price went down -7.031%.
Which hedge fund is a major shareholder of Erasca?
Currently, no hedge funds are holding shares in ERAS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Erasca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.64 (8.56% Upside)
$20.64 (8.56% Upside)
Hedge Fund Trend
Increased
By 343.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 19.2%
Last 30 Days ▲ 33.6%
Last 30 Days ▲ 33.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
400.50%
12-Months-Change
Fundamentals
Return on Equity
-34.48%
Trailing 12-Months
Asset Growth
-18.92%
Trailing 12-Months
Company Description
Erasca
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
ERAS Stock 12 Month Forecast
Average Price Target
$20.64
▲(8.56% Upside)
Technical Analysis
Arcturus Therapeutics
―
Arvinas Holding Company
―
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
10.85% Insiders
9.59% Mutual Funds
0.16% Other Institutional Investors
68.83% Public Companies and
Individual Investors